Similarly, a murine anti-human CD133 antibody (AC133) conjugated to a potent chemotherapeutic agent, monomethyl auristatin F (MMAF), significantly reduced the self-renewal capacity of CD133+ hepatic CSCs and subsequently delayed tumor formation in a SCID mouse model [250]. The gene discussed is PROM1; the disease is neoplasm.